| FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma (NCT00079443) | National Cancer Institute (NCI) | 2004-01-01 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00077155) | National Cancer Institute (NCI) | 2003-12-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies (NCT00072514) | Fred Hutchinson Cancer Center | 2003-08-01 |
| Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (NCT00068315) | National Cancer Institute (NCI) | 2003-07-01 |
| Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation (NCT00058305) | National Cancer Institute (NCI) | 2003-03-01 |
| Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma (NCT00060112) | National Cancer Institute (NCI) | 2003-03-01 |
| Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction (NCT00054483) | National Cancer Institute (NCI) | 2003-01-01 |
| Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma (NCT00054639) | National Cancer Institute (NCI) | 2003-01-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma (NCT00026182) | National Cancer Institute (NCI) | 2001-10-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00022581) | National Cancer Institute (NCI) | 2001-07-01 |
| Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00015912) | National Cancer Institute (NCI) | 2001-07-01 |
| Bortezomib in Treating Patients With Lymphoproliferative Disorders (NCT00023764) | National Cancer Institute (NCI) | 2001-06-01 |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma (NCT00017381) | National Cancer Institute (NCI) | 2001-04-01 |
| Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00012298) | National Cancer Institute (NCI) | 2001-04-01 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia (NCT00005786) | National Cancer Institute (NCI) | 2001-01-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer (NCT00010192) | National Cancer Institute (NCI) | 2000-12-01 |
| Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00006473) | National Cancer Institute (NCI) | 2000-09-01 |
| 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma (NCT00005950) | National Cancer Institute (NCI) | 2000-04-01 |
| Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00005799) | Fred Hutchinson Cancer Center | 1999-11-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (NCT00004241) | National Cancer Institute (NCI) | 1999-10-01 |
| Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies (NCT01678443) | Fred Hutchinson Cancer Center | 1999-09-01 |
| Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NCT00019708) | National Cancer Institute (NCI) | 1999-06-01 |
| Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00073918) | Fred Hutchinson Cancer Center | 1999-02-01 |
| Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma (NCT00003970) | National Cancer Institute (NCI) | 1999-01-01 |
| Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma (NCT00003196) | Fred Hutchinson Cancer Center | 1997-09-01 |
| Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (NCT00002649) | National Cancer Institute (NCI) | 1995-05-01 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |